123 related articles for article (PubMed ID: 2747969)
1. [Ca 19-9 in the diagnosis of pancreatic carcinoma].
Meggiato T; Basso D; Pasquali C; Angonese C; Bellinvia S; Del Favero G; Fabris C; Di Mario F; Plebani M; Pedrazzoli S
Minerva Med; 1989 May; 80(5):431-4. PubMed ID: 2747969
[TBL] [Abstract][Full Text] [Related]
2. CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis.
Farini R; Fabris C; Bonvicini P; Piccoli A; del Favero G; Venturini R; Panucci A; Naccarato R
Eur J Cancer Clin Oncol; 1985 Apr; 21(4):429-32. PubMed ID: 3859414
[TBL] [Abstract][Full Text] [Related]
3. CA 19-9 in serum and pancreatic juice: its role in the differential diagnosis of resectable pancreatic cancer from chronic pancreatitis.
Malesci A; Evangelista A; Mariani A; Bersani M; Bonato C; Basilico M; Montorsi M; Beretta E
Int J Pancreatol; 1988; 3 Suppl 1():S119-23. PubMed ID: 3209865
[TBL] [Abstract][Full Text] [Related]
4. [The use of the carbohydrate antigen CA-19-9, the carcinoembryonic antigen and alpha fetoprotein in the diagnosis of pancreatic cancer].
Skvortsov SV; Kalinin AV; Lytsar' BN
Vestn Ross Akad Med Nauk; 1993; (4):47-9. PubMed ID: 7687486
[TBL] [Abstract][Full Text] [Related]
5. Combined determination of serum CA 19-9 and tissue polypeptide antigen: why no improvement in pancreatic cancer diagnosis?
Basso D; Fabris C; Del Favero G; Panucci A; Plebani M; Angonese C; Leandro G; Dodi G; Burlina A; Naccarato R
Oncology; 1988; 45(1):24-9. PubMed ID: 3422390
[TBL] [Abstract][Full Text] [Related]
6. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma.
Hyöty M; Hyöty H; Aaran RK; Airo I; Nordback I
Eur J Surg; 1992 Mar; 158(3):173-9. PubMed ID: 1356458
[TBL] [Abstract][Full Text] [Related]
7. [Value of plasma testosterone, carcinoembryonic antigen and CA 19-9 in the differential diagnosis of pancreatic carcinoma and chronic pancreatitis].
Jurkowska G; Kulpa J; Skrodzka D; Rogowski F
Pol Arch Med Wewn; 1992 Nov; 88(5):302-9. PubMed ID: 1300550
[TBL] [Abstract][Full Text] [Related]
8. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer].
Safi F; Büchler M; Schenkluhn B; Beger HG
Dtsch Med Wochenschr; 1984 Dec; 109(49):1869-73. PubMed ID: 6209082
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis.
Gentiloni N; Caradonna P; Costamagna G; D'Ostilio N; Perri V; Mutignani M; Febbraro S; Tinari N; Iacobelli S; Natoli C
Am J Gastroenterol; 1995 Jul; 90(7):1069-72. PubMed ID: 7611198
[TBL] [Abstract][Full Text] [Related]
10. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9.
Slesak B; Harlozinska-Szmyrka A; Knast W; Sedlaczek P; van Dalen A; Einarsson R
Cancer; 2000 Jul; 89(1):83-8. PubMed ID: 10897004
[TBL] [Abstract][Full Text] [Related]
11. [The diagnostic significance of carbohydrate antigen 19-9 in pancreatic carcinomas].
Chen YF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Jun; 11(3):229-31. PubMed ID: 2529993
[TBL] [Abstract][Full Text] [Related]
12. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A
Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two newly identified tumor markers (CAR-3 and DU-PAN-2) with CA 19-9 in patients with pancreatic cancer.
Ferrara C; Basso D; Fabris C; Malesci A; Fogar P; Meggiato T; Panozzo MP; Scalon P; Del Favero G; Plebani M
Tumori; 1991 Feb; 77(1):56-60. PubMed ID: 1673269
[TBL] [Abstract][Full Text] [Related]
14. [Use of the CA 19-9 tumor marker in the diagnosis of pancreatic carcinoma].
Kausitz J; Lesný P; Belan V
Bratisl Lek Listy; 1993 Apr; 94(4):201-3. PubMed ID: 8353764
[TBL] [Abstract][Full Text] [Related]
15. CAR-3 and CA 19-9 serum levels in pancreatic cancer: any differences between two epitopes of the same mucin-like glycoprotein?
Meggiato T; Basso D; Fabris C; Fogar P; Panozzo MP; Plebani M; Faggian D; Scalon P; Ferrara C; Del Favero G
Dis Markers; 1990; 8(4):171-7. PubMed ID: 1708317
[TBL] [Abstract][Full Text] [Related]
16. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
17. How does liver dysfunction influence serum CA 19-9 in pancreatic cancer?
Basso D; Fabris C; Del Favero G; Piccoli A; Angonese C; Pasquali C; Castoro C; Plebani M; Leandro G; Burlina A
Ital J Gastroenterol; 1990 Feb; 22(1):1-6. PubMed ID: 2131920
[TBL] [Abstract][Full Text] [Related]
18. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9.
Safi F; Roscher R; Beger HG
Hepatogastroenterology; 1989 Dec; 36(6):419-23. PubMed ID: 2613165
[TBL] [Abstract][Full Text] [Related]
19. [Blood CA 19-9 in the diagnosis of carcinoma of the pancreas: a critical approach].
Angonese C; Basso D; Del Favero G; Fabris C; Tremolada C; Plebani M; Burlina A; Naccarato R
Ann Ital Med Int; 1987; 2(2):138-42. PubMed ID: 3275279
[No Abstract] [Full Text] [Related]
20. The diagnostic significance of carbohydrate antigen CA 19-9 in serum and pancreatic juice in pancreatic carcinoma.
Chen YF; Mai CR; Tie ZJ; Feng ZT; Zhang J; Lu XH; Lu GJ; Xue YH; Pan GZ
Chin Med J (Engl); 1989 May; 102(5):333-7. PubMed ID: 2509154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
